

## US PATENT FOR REGULATION OF BARD1 EXPRESSION

- **US Patent No 10,273,475 issued protecting siRNA that target and reduce the expression of BARD1 9'L in cancer**

**Perth, Australia, 1 May 2019:** BARD1 Life Sciences Limited (ASX:BD1), a medical technology company developing non-invasive cancer diagnostics, today announced that it has received Issue Notification from the United States Patent and Trademark Office (USPTO) confirming the issue of United States Patent no 10,273,475 on 30<sup>th</sup> April 2019.

US Patent no 10,273,475 entitled "Regulation of BARD1 expression by non-coding RNA" names Irmgard Irminger-Finger and Maxim Pilyugin as inventors and has been assigned to BARD1 Life Sciences Limited.

The issued US patent claims are directed to siRNA that target and reduce the expression of the novel long non-coding BARD1 RNA molecule BARD1 9'L. BARD1 9'L is a therapeutic target due to its overexpression in cancer and siRNA could be potentially used for treatment of cancer. The patent application was filed on 12 July 2015 and is due to expire on 12 July 2035.

A US continuation application has been filed to further protect methods to detect BARD1 9'L RNA and methods of treatment of cancer using siRNA.

- ENDS -

### FOR MORE INFORMATION PLEASE CONTACT:

**Peter Gunzburg**  
Chairman  
E [peter@bard1.com](mailto:peter@bard1.com)

**Dr Leeorne Hinch**  
CEO  
E [leeorne@bard1.com](mailto:leeorne@bard1.com)  
M +61 400 414 416

### ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian medical technology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1 owns a proprietary tumour marker platform with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers. Additional diagnostic projects will be evaluated for other cancers. BARD1's vision is to detect cancer early and save lives. For more information on BARD1, see [www.bard1.com](http://www.bard1.com).

### ABOUT THE BARD1 INTELLECTUAL PROPERTY PORTFOLIO

BARD1 has established a strong intellectual property (IP) position protecting its biomarker platform technology and products with claims covering various BARD1 DNA and protein sequences, methods of diagnosis and treatment, and use in multiple cancers. The Company owns or licenses 5 patent families with 11 granted and 19 pending patents covering its technology, products and uses across key marketplaces including the US, Europe, China and Japan.

Figure 1: BARD1 Patent Status

Patent Family	Title	Granted	Pending	Expiry
PCT/FR01/02731	Truncated BARD1 protein and its diagnostic and therapeutic uses	US, JP		2021
PCT/IB2011/053635	BARD1 isoforms in lung and colorectal cancer and use thereof	US, JP, JP div, IL, CN, CN div, AU	US divisional, EP, CA, BR, SG, HK	2031*

PCT/IB2011/054194	Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof	US	US divisional, EP	2031*
PCT/EP2014/073834	Lung Cancer Diagnosis		US, EP, CA, JP, IL, CN, AU, SG, KR, HK	2034*
10,273,475	Regulation of BARD1 expression by non-coding RNA	US	US continuation	2035

\* Plus any extension of term in the US due to prosecution delay

### DISCLAIMER

This announcement contains “forward-looking statements” and “forward-looking information”, including statements and forecasts relating to the Company. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “is expecting”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes”, or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might”, or “will” be taken, occur or be achieved. Such information is based on assumptions and judgements of management regarding future events and results. The purpose of forward-looking information is to provide the audience with information about management’s expectations and plans. Readers are cautioned that forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company and/or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information.